ARA-290: The Non-Haematopoietic EPO Peptide With Neuroprotective and Anti-Inflammatory Action

ARA-290 (Cibinetide, Araim Pharmaceuticals) is an 11-amino-acid peptide derived from the helix B surface peptide of erythropoietin (EPO). EPO is best known for stimulating red blood cell production through the classical EPO receptor (EPOR homodimer), but it also activates a tissue-protective receptor — the INNATE repair receptor (IRR) — that mediates cytoprotective, anti-inflammatory, and regenerative effects without haematopoiesis. ARA-290 was designed to selectively activate the IRR while having no activity at the classical EPOR, separating EPO's tissue-protective functions from its blood-production effects.

EPO Biology: Haematopoietic vs Tissue-Protective Receptors

EPO activates two distinct receptor complexes:

• Classical EPOR (homodimer): Present on erythroid progenitors in bone marrow. Mediates haematopoiesis — red blood cell production, haematocrit elevation. Also responsible for EPO's cardiovascular risk at supraphysiological doses (polycythaemia, thromboembolic events).
• INNATE Repair Receptor (IRR, heterodimer of EPOR + βc CD131): Present on neurons, macrophages, epithelial and endothelial cells in peripheral and central tissues. Mediates tissue protection, anti-inflammation, neural repair, and cytoprotection. ARA-290 activates only this receptor.

Mechanism of Action

ARA-290 binding to the IRR activates several cytoprotective pathways:

• NF-κB inhibition: Reduces pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
• Autophagy promotion: Activates cellular recycling of damaged components — a key mechanism in neuroprotection
• Small fibre nerve regeneration: Stimulates axonal regrowth in peripheral small fibres (C and Aδ fibres responsible for pain transmission)
• Macrophage polarisation: Promotes anti-inflammatory (M2) macrophage phenotype
• Anti-apoptotic signalling: Activates PI3K/Akt survival pathways in stressed cells

Neuropathy Clinical Data

The most clinically advanced application for ARA-290 is painful neuropathy. Phase 2 trial data in patients with sarcoidosis-related small fibre neuropathy (SFN) showed:

• Significant improvement in spontaneous pain scores
• Increased corneal nerve fibre density (CNFD) as measured by corneal confocal microscopy — objective evidence of small fibre regeneration
• Improved quality of life measures (fatigue, mood, functional scores)
• Good tolerability: no haematological changes, no EPO-related cardiovascular risk signals

A separate Phase 2 study in painful diabetic peripheral neuropathy (DPN) showed similar trends in pain reduction and nerve fibre density improvement.

Anti-Inflammatory and Organ Protection Applications

Beyond neuropathy, ARA-290's IRR-mediated anti-inflammatory mechanism has research applications across multiple organ systems:

• Cardiac protection: Reduction of ischaemia-reperfusion injury in cardiac models; reduction of infarct-related inflammation
• Renal protection: Anti-inflammatory and anti-fibrotic effects in AKI and CKD models
• Autoimmune inflammation: Modulation of immune activity in sarcoidosis models (the initial clinical application)
• Neuroinflammation: CNS microglial modulation and neuroprotection in inflammatory neurological disease models

Why ARA-290 vs Full EPO Matters for Research Safety

Full EPO at therapeutic doses for tissue protection necessarily elevates haematocrit, creating polycythaemia and thromboembolic risk — making it unsuitable for most research applications outside severe anaemia. ARA-290's complete selectivity for the IRR versus the haematopoietic EPOR means researchers can investigate EPO's tissue-protective biology at any dose without haematological confounders. This is a critical experimental advantage for mechanistic research.

Frequently Asked Questions

How does ARA-290 differ from EPO in terms of safety?

Full EPO elevates red blood cells and haematocrit, creating cardiovascular risk. ARA-290 has no activity at the classical EPOR, producing no haematological changes — researchers can use it at tissue-protective doses without polycythaemia risk.

What is the status of ARA-290 clinical development?

ARA-290 has completed Phase 2 trials for sarcoidosis neuropathy and diabetic neuropathy under the name Cibinetide. Phase 3 trials and regulatory pathway discussions are ongoing as of 2025.

References

• Brines M, et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. PNAS, 105(31), 10925–10930.
• van Velzen M, et al. (2014). Pilot study of ARA 290 in sarcoidosis patients. Molecular Medicine, 20, 80–89.
• Niesters M, et al. (2016). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and pain. Molecular Medicine, 22, 436–445.